../ IS  
┌tgefi­ gŠ­askjal: Lei­beiningar
Skjaln˙mer: RklÝn-320
┌tg.dags.: 04/12/2018
┌tgßfa: 4.0 COMP

Samheiti: Cartilage Oligomeric Matrix Protein
Hide details for Sřnataka, geymsla og sřnasending Sřnataka, geymsla og sřnasending
Ger­ sřnis : Sermi e­a heparÝn-plasma (ekki EDTA- e­a Citrat-plasma)
Sřni teki­ Ý serum glas me­ rau­um tappa me­ geli (gul mi­ja) e­a Ý lithÝum heparÝn glas me­ grŠnum tappa me­ geli (gul mi­ja) .
Litakˇ­i samkvŠmt Greiner

Magn: 1 mL
Geymsla sřnis: Frystir.
Sřnasending: Hra­sending ß ■urrÝs.
Hide details for Heiti tilvÝsunarannsˇknastofu og heimilisfangHeiti tilvÝsunarannsˇknastofu og heimilisfang
MVZ Labor PD Dr. Volkmann und Kollegen GbR
Kriegsstrasse 99
76133 Karlsruhe

Tel:á 0721 85000-0
Fax: 0721 85000-199

Hide details for HeimildirHeimildir

Cartilage Oligomeric Matrix Protein

MVZ Labor PD Dr. Volkmann und Kollegen GbR 1 07.10.2011

Akronym COMP
Material Serum oder Heparin-Plasma, 1 mL, gekŘhlt (4 - 8 ░C)
Bitte kein EDTA-Blut oder Citrat-Blut / EDTA-Plasma oder Citrat-Plasma einsenden!
Referenzbereich [U/L] Risiko der aggressiven Gelenkzerst÷rung
< 12 gering
12 - 15 erh÷ht
> 15 hoch
Methode Sandwich-Elisa mit zwei monoklonalen COMP-Antik÷rpern unterschiedlicher Epitop-spezifitńten. Detektor Peroxidase/Tetramethylbenzidin.
Qualitńtskontrolle intern
Anforderungsschein Download und Analysenposition
AuskŘnfte Endokrinologie / RIA-Labor

Frˇ­leikur: Cartilage oligomeric matrix protein (COMP), also known as thrombospondin-5, is an extracellular matrix (ECM) protein primarily present in cartilage ( Cartilage is a resilient and smooth elastic tissue, rubber-like padding that covers and protects the ends of long bones at the joints, and is a structural component of the rib cage, the ear, the nose, the bronchial tubes, the intervertebral discs, and many other body components. It is not as hard and rigid as bone, but it is much stiffer and much less flexible than muscle) .Arthritis is a chronic disease with a significant impact on the population. It damages the cartilage, synovium, and bone of the joints causing pain, impairment, and disability in patients. Current methods for diagnosis of and monitoring the disease are only able to detect clinical manifestations of arthritis late in the process. However, with the recent onset of successful treatments for rheumatoid arthritis and osteoarthritis, it becomes important to identify prognostic factors that can predict the evolution of arthritis. This is especially critical in the early phases of disease so that these treatments can be started as soon as possible to slow down progression of the disease. A valuable approach to monitor arthritis would be by measuring biological markers of cartilage degradation and repair to reflect variations in joint remodeling. One such potential biological marker of arthritis is cartilage oligomeric matrix protein (COMP). In various studies, COMP has shown promise as a diagnostic and prognostic indicator and as a marker of the disease severity and the effect of treatment. This review highlights the progress in the utilization of COMP as a biomarker of arthritis.


Ingibj÷rg Loftsdˇttir
Sigr˙n H PÚtursdˇttir
Gu­mundur Sig■ˇrsson
KristÝn Sigurgeirsdˇttir



═sleifur Ëlafsson


Sigr˙n H PÚtursdˇttir

Upp »

Skjal fyrst lesi­ ■ann 06/04/2012 hefur veri­ lesi­ 604 sinnum